NCT07313579 Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer
| NCT ID | NCT07313579 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ukrainian Society of Clinical Oncology |
| Condition | Gastric Cancer (GC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2030-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2025-12-01 with a primary completion date of 2030-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study investigates the outcomes of hyperthermic intraperitoneal chemoperfusion (HIPEC) in combination with curative-intent gastrectomy in resectable locally-advanced and limited-metastatic (low peritoneal cancer index) gastric cancer.
Eligibility Criteria
Inclusion Criteria: 1. Age 18-80 2. Hystologicaly proven gastric adenocarcinoma 3. ECOG status 0-1 4. Written consent to participate in the study 5. Medically and technically operable gastric tumor 6. Only T4a or T4b tumours with any peritoneal cytology status 7. Cytologically positive peritoneal washings (cyt+) with any T and N criteria 8. Adequate haemopoetic, renal and hepatic function (Hb \> 120, PLT \> 150\*10\^9/l, ALT \< 60, AST \<40, total bilirubin \< 21 µmol/l, Creatinine clearance (male - 90-140, female - 80-130 ml/min) Exclusion Criteria: 1. Pregnancy/breastfeeding 2. ECOG status 2-4 3. Concomitant malignancy 4. Mitomycin and/or Cisplatin hypersensitivity 5. Uncontrollable chronic diseases 6. Patients with coexisting malignancy other than basal cell carcinoma of the skin within the last five years. 7. Presence of metastases other than regional or peritoneal (such as liver, lungs, bone, brain, distant lymph nodes) 8. History of allergic reactions associated with cisplatin and Mitomycin C 9. Patients with psychiatric illness/social situations with impaired compliance 10. •Refusal to participate
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07313579 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Gastric Cancer (GC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07313579 currently recruiting?
Yes, NCT07313579 is actively recruiting participants. Contact the research team at alekseydobrzhanskiy@gmail.com for enrollment information.
Where is the NCT07313579 trial being conducted?
This trial is being conducted at Kyiv, Ukraine.
Who is sponsoring the NCT07313579 clinical trial?
NCT07313579 is sponsored by Ukrainian Society of Clinical Oncology. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.